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Genome-wide association studies (GWAS) have identified over 100 risk loci for 
schizophrenia, but the causal mechanisms remain largely unknown. We performed a 
transcriptome-wide association study (TWAS) integrating expression data from brain, 
blood, and adipose tissues across 3,693 individuals with schizophrenia GWAS of 
79,845 individuals from the Psychiatric Genomics Consortium. We identified 157 
genes with a transcriptome-wide significant association, of which 35 did not overlap 
a known GWAS locus; the largest number involved alternative splicing in brain. 
42/157 genes were also associated to specific chromatin phenotypes measured in 
121 independent samples (a 4-fold enrichment over background genes). This high 
through put connection of GWAS findings to specific genes, tissues, and regulatory 
mechanisms is an essential step toward understanding the biology of schizophrenia 
and moving towards therapeutic interventions. 
 
Introduction 
Genome-wide association studies (GWAS) have yielded thousands of robustly 
associated variants for schizophrenia (SCZ) and many other complex traits, but 
relatively few of these associations have implicated specific biological mechanisms 
as GWAS association signals often span many putative target genes, may affect 
gene expression through regulatory or structural elements, and may affect genes at 
considerable genomic distances via chromatin looping. A growing body of research 
has demonstrated the enrichment of SCZ GWAS risk variants and heritability within 
regulatory elements identified through maps of chromatin modifications and 
accessibility. Since chromatin modifications are themselves under genetic control a 
causal mechanism for SCZ loci could lead from genetic variation to chromatin 
modifiers to gene expression and finally to disease risk. Indeed, QTLs for chromatin 
(and other molecular phenotypes) are enriched within GWAS associations, further 
supporting this hypothesis. 
 
In this work, we leveraged large gene expression cohorts from multiple tissues, as 
well as splice variants in brain, to perform a transcriptome-wide association study 
(TWAS)  in a large SCZ GWAS data set  to identify genes whose expression is 
associated with SCZ and mediated by genetics. We subsequently performed a 
TWAS for a diverse set of chromatin phenotypes to identify SCZ susceptibility genes 
that are also associated with specific regulatory elements. To our knowledge, this is 
the first TWAS to integrate analysis of gene expression, differential splicing, and 
chromatin variation, moving beyond top SNPs to implicate SCZ-associated 
molecular features across the regulatory cascade (Figure 1A). 
 
Results 
TWAS for schizophrenia identifies new susceptibility genes. 
We analyzed gene-expression and genome-wide SNP-array data in 3,693 
individuals across four expression reference panels: RNA-seq from the dorsolateral 
prefrontal cortex of 621 individuals (including 283 schizophrenia cases, 47 bipolar 
cases, and 291 controls) collected by the CommonMind Consortium (CMC), 
expression array data measured in peripheral blood from 1,245 unrelated control 
individuals from the Netherlands Twin Registry (NTR), expression array data 
measured in blood from 1,264 control individuals from the Young Finns Study (YFS), 
and RNA-seq data measured in adipose tissue from 563 control individuals from the 
Metabolic Syndrome in Men study (METSIM); pre-computed weights from ref.  were 
used for the YFS/METSIM studies. We further characterized splicing events in the 
CMC brain RNA-seq data (Methods). The average cis and trans estimates of the 
SNP heritability of expression (hg 2, Methods) were highly significant in each panel, 
with a total of a total of 18,084 genes summed across the four panels (10,819 unique 
genes; Supplementary Table 1), as well as an additional 9,009 splicing events in the 
brain (in 3,908 unique genes; Supplementary Table 1) exhibiting nominally 
significant cis-hg 2 (P < 0.01 by likelihood ratio test). 
 
We performed a TWAS using each of the four gene-expression reference panels and 
summary-level data from the Psychiatric Genomics Consortium (PGC) schizophrenia 
GWAS of 79,845 individuals1 to identify genes associated with schizophrenia (Fig. 1 
and Supplementary Fig. 1a). Briefly, this approach integrated information from 
expression reference panels (SNP–expression correlation), GWAS summary 
statistics (SNP–schizophrenia correlation), and linkage disequilibrium (LD) reference 
panels (SNP–SNP correlation) to assess the association between the cis-genetic 
component of expression and phenotype (expression–schizophrenia correlation). In 
practice, the expression reference panel was used as the LD reference panel, and 
cis-SNP-expression effect sizes were estimated with a sparse mixed linear model 
(Methods). Because schizophrenia is a highly polygenic trait, we expected these 
control reference samples to carry disease-affecting regulatory variants. By 
leveraging genetic predictors of expression, our approach was not affected by 
reverse causality (disease → expression), but pleiotropic effects on expression and 
trait could not be ruled out without additional analyses (Discussion). 
 
The TWAS identified 247 transcriptome transcriptome-wide-significant gene– 
schizophrenia and intron–schizophrenia associations (summed across expression 
reference panels) for a total of 157 unique genes, including 49 genes that were 
significant in more than one expression panel (Fig. 2, Table 1, Supplementary Fig. 2 
and Supplementary Tables 2 and 3). We observed no significant differences when 
performing the TWAS by using brain expression data from schizophrenia/ bipolar 
cases or controls separately, thus confirming that the presence of cases in the 
reference panel did not affect our results (Supplementary Note and Supplementary 
Table 4). We observed hotspots of multiple TWAS-associated genes at 33 loci 
(defined by genes < 500 kb apart). However, only 6/33 loci exhibited evidence of 
statistically independent genetic effects in a summary-based joint test, thus 
suggesting that most of these loci could be explained by a single underlying genetic 
effect (Methods and Supplementary Table 3). Across all TWAS associations, the 
implicated gene was the nearest gene to the top SNP at the locus in only 56% of 
instances (with the 10,819 cis-heritable genes used as background; this value 
decreased to 24% of instances when all 26,469 known RefSeq genes were used), 
thus underscoring previous findings. We confirmed that the summary-based 
approach was consistent with individual-level predictions by using individual-level 
PGC data, and we replicated the associations in aggregate by using out-of-sample 
schizophrenia plus bipolar phenotypes (Supplementary Note, Supplementary Tables 
5 and 6, and Supplementary Figs. 1a and 3–5). 
 
 
Fig. 1 | Schematic of the TWAS approach. Illustration of the TWAS approach: the 
genetic predictor of gene expression (Eg) is learned in are reference panel (top), 
integrated with schizophrenia GWAS association statistics to infer schizophrenia–Eg 
association (middle), and further integrated with individual-level chromatin 
phenotypes to infer genes with schizophrenia and chromatin–Eg associations 




Of the 108 published PGC GWAS regions1, 47 regions were located near (± 500 kb) 
at least one TWAS gene (accounting for 122/157 genes), and the remaining 35/157 
genes implicated novel targets. The GWAS association statistics at novel TWAS loci 
were often well below genome-wide significance (Supplementary Fig. 6), and we 
hypothesized that some of the new discoveries might be driven by the TWAS 
aggregating partially independent effects on schizophrenia that operate through a 
single gene. As evidence of this model, the TWAS association was stronger than the 
lead SNP for 27% of TWAS associations that did not overlap a genome-wide-
significant SNP, but for only 3% of TWAS associations that did overlap a 
genomewide- significant SNP (Fisher's exact P = 8.1 × 10−7). Across all TWAS 
associations, 21/247 were more significant than the lead GWAS SNP, and the 
percentage of cis expression heritability that was explained by the top expression 
QTL (eQTL) for these 21 genes was significantly lower than that for the rest (56% 
versus 88%, t-test P = 9.6 × 10−5), a result indicative of secondary QTL effects. We 
excluded the major histocompatibility complex region (chromosome (chr) 6: 28–34 
Mb) from our primary analyses because of its complex haplotype and LD structure. 
However, as a positive control, we specifically tested the C4A gene, which has 
recently been fine mapped for schizophrenia4 and lies inside the major 
histocompatibility complex region, and we confirmed a highly significant TWAS 





Fig. 2 | Schizophrenia TWAS associations and polygenic effects. Top, Manhattan 
plot of all TWAS associations. Each point represents a single gene tested, with 
physical position plotted on the x axis and Z score of association between gene and 
schizophrenia plotted on the y axis. Transcriptome-widesignificant associations are 
highlighted as red points, with jointly significant independent associations (Methods) 
labeled with gene names and color coded according to expression reference (red, 
CMC; blue, METSIM; purple, YFS; green, NTR; black, all). Bottom, polygenic TWAS 
effects across reference tissues. Out-of-sample schizophrenia prediction R2 for GE-
PRS as a function of significance cutoff. Significant correlations (after Bonferroni 
correction for number of thresholds tested) are indicated with an asterisk, and the 
most significant P value is reported. Rightmost panel shows prediction from all 
tissues jointly (black) and from CMC brain genes plus splicing events jointly (red). R2 
was computed after subtraction of ancestry principal components and conversion to 
liability scale with a population prevalence of 1%. 
 
Splicing events in the brain accounted for 46 transcriptomewide- significant gene 
associations (of which ten were at novel loci), a number comparable to the 44 
significant gene associations from the brain (Table 1 and Supplementary Table 3), 
although splicing events accounted for 30% fewer significantly cis-heritable genes 
than total expression (Supplementary Table 1). Overall, 20/46 associations 
corresponded to genes that were not tested in the analysis of total gene expression, 
owing to nonsignificant expression heritability, and 19 of the remaining 26 
associations did not have a transcriptome- wide-significant association for total gene 
expression. This result was consistent with the recent observation that splicing QTLs 
are typically independent of eQTLs at the same gene. We caution that effect 
direction for splicing events is difficult to interpret because alternatively spliced exons 
are often negatively correlated (Supplementary Note and Supplementary Fig. 7). 
Although the largest number of associations came from the brain, the enrichment 
was not striking after the total number of heritable genes was accounted for (Table 
1), thus suggesting that expression-data quality and sample size currently are more 







Fig. 3 | Chromatin TWAS associations compared with top eSNP–cQTL associations. 
Number of unique genes significantly associated with a chromatin peak after 
Bonferroni correction for a given distance from the gene (x axis), determined by 
using the top eSNP in the chromatin cohort (left) or using chromatin TWAS from all 
reference panels (right). Results from CEU and YRI populations are shown at top 
and bottom, respectively. 
 
QTLs are typically independent of eQTLs at the same gene. We caution that effect 
direction for splicing events is difficult to interpret because alternatively spliced exons 
are often negatively correlated (Supplementary Note and Supplementary Fig. 7). 
Although the largest number of associations came from the brain, the enrichment 
was not striking after the total number of heritable genes was accounted for (Table 
1), thus suggesting that expression-data quality and sample size currently are more 
important than tissue specificity in finding significant associations. TWAS 
associations may be caused by coincidental overlap between eQTLs and noncausal 
disease variants at a GWAS locus, a possibility that we investigated through formal 
colocalization and conditional analyses. First, we used the COLOC method to 
estimate the posterior probability of a single shared causal variant for TWAS 
implicated genes and schizophrenia by using the marginal association statistics. We 
calibrated a 5% false-discovery threshold for considering a gene ‘colocalized’, using 
randomly selected heritable genes in the same schizophrenia GWAS regions 
(Methods). Colocalization between eQTLs and schizophrenia was observed for 55% 
of the TWAS-implicated genes (Supplementary Fig. 8 and Supplementary Table 3). 
We note that COLOC's posterior is highly dependent on the prior probability of a 
single shared causal variant (Supplementary Fig. 9) and is conservative when 
multiple causal variants mediate the effects on expression and trait, so that 
colocalization at the remaining loci may be underestimated. For the 45% genes that 
did not significantly colocalize, the percentage of cis expression heritability explained 
by the top eQTL was lower than that explained by the rest (79% versus 89%), thus 
suggesting secondary effects; however, the difference was not statistically 
significant. Second, conditioning on the predicted expression of a TWAS-associated 
gene (using summary-level data; Methods) reduced the χ2 of the lead GWAS SNP 
at the locus (including genome-wide-significant and nonsignificant loci) from 42 to 10 
on average, and explained more of the association signal than did conditioning on 
the corresponding top eQTL (Supplementary Table 7). For the 43 lead GWAS SNPs 
at genome-wide-significant loci that were correlated (r2 > 0.05) with the predicted 
expression of at least one TWAS-significant gene (out of 47 overlapping index 
SNPs), joint conditioning on the predicted expression of all such genes decreased 
the median SNP P value from P = 1.2 × 10−10 to P = 0.028 (Methods and 
Supplementary Table 8). Given that the expression predictor typically captures only 
60–80% of the cis component of gene expression at the expression-panel sample 
sizes used here, the complete elucidation of the cis component may potentially 
explain the entire GWAS signal at these loci. This schizophrenia GWAS dataset1 
has recently been evaluated in a TWAS with gene expression in blood through 
summary-based Mendelian randomization (SMR), which identified 16 transcriptome- 
wide-significant associated genes (in contrast to 157 identified here). Of the 16 gene 
associations identified by SMR, 12 were tested in our study in blood; all replicated at 
nominal P <0.05 (with consistent sign), and 9 were transcriptome-wide significant—a 
striking concordance given the different methods and independent expression panels 
used. 
 
Functional validation of TWAS-associated genes by using 
chromatin-interaction data. We leveraged recently published chromatin-interaction 
(Hi-C) data in the developing human brain to investigate whether TWAS-associated 
genes were supported by physical chromatin interactions that occur during brain 
development (Supplementary Fig. 1b). We used the Hi-C data to construct a set of 
comparison schizophrenia-risk genes on the basis of 3D chromatin interactions 
between gene transcription start sites (TSSs) and SNPs in the fine-mapped 95%-
causal credible set (Methods). This procedure yielded a set of 59 loci with both 
TWAS and fine-mapped Hi-C data, containing 474 Hi-C-predicted schizophrenia- risk 
genes. The 474 Hi-C-predicted genes overlapped with 105/157 TWAS-associated 
genes (Supplementary Fig. 10; Fisher's exact test P = 1.03 × 10−18, odds ratio = 
4.68 compared with random heritable genes at these loci), thus indicating that most 
of the TWAS associated genes were supported by 3D chromatin interactions with a 
schizophrenia SNP in the developing brain. The TWAS associations were also 
significantly correlated with higher expression during mid fetal developmental in 
independent samples (P < 0.05/19; Supplementary Note and Supplementary Figs. 
11 and 12), thus further underscoring the etiological relevance of mechanisms active 




Fig. 4 | Chromatin and schizophrenia TWAS association at PPP2R3C. Example 
association of PPP2R3C gene expression and schizophrenia and four nearby 
chromatin peaks. a, Locus schematic showing all nearby genes and chromatin 
peaks; TWAS-associated features are highlighted in blue and green. b–g, Left, 
Manhattan plots of marginal association statistics before and after conditioning on 
the TWAS-predicted expression (colored and dark dots, respectively). Dashed line 
shows the local significance threshold after Bonferroni correction for the number of 
SNPs. Right, relationship between marginal GWAS–QTL association (y axis) and the 
correlation (x axis) between TWAS-predicted expression (GEpred estimated in the 
1000 Genomes reference) and marginal GWAS–QTL association. The color of each 
point reflects the eQTL effect size of the expression used for GEpred, and the size of 
each point reflects the absolute significance of the eQTL. b, Schizophrenia GWAS 
association. c, PPP2R3C expression phenotype used for TWAS prediction and 
associated with schizophrenia/chromatin. d, First TWAS-associated H3K27ac peak 
in CEU. e, Second TWAS-associated H3K27ac peak in CEU. f, First 
TWASassociated H3K4me1 peak in CEU. g, Second TWAS-associated H3K4me1 
peak in CEU. Additional examples and simulations in Supplementary Note and 
Supplementary Figs. 32–34. 
 
Polygenic TWAS signal largely explained by expression in the brain. To assess 
the full polygenic architecture of the TWAS associations, we relaxed the 
transcriptome-wide-significance threshold and constructed gene-based polygenic 
risk scores (GE-PRS) from their predicted expression in the CMC (schizophrenia 
plus bipolar) case–control samples (Supplementary Fig. 1c). For each out-of-sample 
individual, the GE-PRS was the sum of predicted expression weighted by its signed 
schizophrenia TWAS Z score (Methods). The GE-PRS was significantly associated 
with schizophrenia status (conditioned on ancestry) across the full spectrum of 
TWAS association P values (Fig. 2), as seen with SNP-based polygenic scores. 
Although the prediction was significant in all tissues individually, there was clear 
evidence of an increased effect in the brain (in contrast to the transcriptome-wide-
significant results), and the prediction from the brain (genes and splicing events) 
captured 92% of the joint prediction from all tissues (Fig. 2 and Supplementary Fig. 
13). A GE-PRS from actual measured expression and differential splicing in the brain 
was significant but substantially less so than the genetic GE-PRS (Supplementary 
Fig. 13). According to polygenic theory36,37, the best TWAS GE-PRS was 
estimated to account for 26% of the total schizophrenia SNP heritability, thus 
providing an upper bound on the amount of trait variance that could be mediated by 





Fig. 5 | Chromatin and schizophrenia TWAS association at KLC1. Example 
association of KLC1 splice event and schizophrenia, with evidence of chromatin 
interaction in Hi-C from the developing brain. a, Locus schematic with all nearby 
genes and chromatin peaks; TWAS-associated features are highlighted in blue and 
green. Hi-C germinal zone (GZ) and cortical and subcortical plate (CP) rows show 
the significance of the Hi-C chromatin interaction between the 10-kb block containing 
the associated chromatin peaks (gray, with neighboring white blocks not tested) and 
every other 10-kb block in the region (with 10 kb being the highest resolution for this 
Hi-C data). Darker-red shading indicates higher significance, and interactions 
significant at 0.01 FDR are labelled with asterisks. The most significant interaction in 
the locus overlaps the KLC1 promoter. The interactions are shown for fetal-brain 
data from CP and GZ, and corresponding topological domains are outlined with solid 
black lines. b–f, Left, Manhattan plots of marginal association statistics before and 
after conditioning on the TWAS-predicted expression (colored and dark dots, 
respectively). Dashed line shows local significance threshold after Bonferroni 
correction for number of SNPs. Right, relationship between the marginal GWAS–
QTL association (y axis) and the correlation (x axis) between TWASpredicted 
expression (GEpred estimated in the 1000 Genomes reference) and marginal 
GWAS–QTL association. The color of each point reflects the eQTL effect size of the 
expression used for GEpred, and the size of each point reflects the absolute 
significance of the eQTL. b, Schizophrenia GWAS association. c, KLC1 total 
expression. Both panels show independence from the TWAS-predicted expression. 
d, KLC1 splicing-event phenotype used for TWAS prediction and associated with 
schizophrenia/chromatin. spQTL, splicing QTL. e, TWAS-associated H3K4me1 
chromatin peak in YRI. f, TWAS-associated H3K4me3 chromatin peak in YRI. 
Additional examples and simulations in Supplementary Note and Supplementary 
Figs. 32–34. 
 
Chromatin TWAS identifies specific regulatory features associated with 
expression. We next sought to identify relationships between the expression of 
TWAS genes and cis regulatory elements marked by chromatin activity. We used 
population-level chromatin immunoprecipitation–DNA sequencing (ChIP–seq) 
chromatin phenotypes measured in 76 HapMap Yoruba in Ibadan, Nigeria 
(YRI) lymphoblastoid cell lines (LCLs) for acetylated histone H3 Lys27 (H3K27ac; 
marking active enhancers), methylated H3 Lys4 (H3K4me1; enhancers), 
trimethylated H3 Lys4 (H3K4me3; promoters), and DNase I–hypersensitive sites 
(DHS; open chromatin), and in 45 HapMap Utah residents with Northern and 
Western European ancestry from the CEPH collection (CEU) LCLs for H3K27ac, 
H3K4me1, H3K4me3, the regulatory transcription factor PU1, and RNA polymerase 
II (RPB2, associated with active transcription). For each of the nine chromatin 
phenotypes, regions with an excess of ChIP–seq reads were segmented into local 
peaks, and the chromatin abundance within each peak was treated as a quantitative 
trait. Both cohorts additionally had gene expression measured by RNA-seq in the 
same samples, and we confirmed that the genetic correlation was highly significant 
between expression and each chromatin mark (as well as between different 
chromatin marks) and persisted as far as 500 kb from the TSS (Supplementary 
Figs. 14–16, Supplementary Table 9 and Methods). We applied individual-level 
TWAS methods to predict expression of the 10,819 significantly heritable genes and 
9,009 differentially spliced introns into samples with chromatin phenotypes and 
searched for expression–chromatin associations (Fig. 1 and Supplementary Fig. 1d). 
Prediction was performed from expression to chromatin-phenotype samples (instead 
of from chromatin-phenotype to expression samples) because of higher prediction 
accuracy in the larger expression panels, but this choice was agnostic to the 
direction of causality (Supplementary Note). Our approach yielded an average of 
2.4× more Bonferroni-significant expression– chromatin associations than the 
conventional approach using in-sample lead cis expression-associated SNP 
(eSNP)–chromatin QTL (cQTL) overlap, primarily because of associations > 10 kb 
from the TSS (Fig. 3 and Supplementary Fig. 17). We obtained similar results when 
overlapping all cis eQTLs and in simulation (Supplementary Note, Supplementary 
Figs. 18–20 and Supplementary Table 10). Across all tissues, 806 unique genes had 
a transcriptome-wide-significant association (Methods) with at least one chromatin 
phenotype (Supplementary Fig. 18b and Supplementary Table 11), and 4,294 genes 
were significant at the 10% (per-phenotype) false discovery rate (FDR) used in 
previous studies (Supplementary Table 12). In contrast, only 224 of 9,009 splicing 
events in the CMC had a transcriptome-wide-significant chromatin association, 
corresponding to two- to three-times-fewer associations than we identified by using 
total CMC gene expression (depending on the chromatin phenotype; Supplementary 
Table 13). Half of the chromatin associations were distal (10–500 kb from the TSS), 
and these were significantly enriched in Hi-C interactions in LCLs6 relative to 
random (distance-matched) gene–peak pairs (Supplementary Figs. 1g and 21–24). 
No other differences in chromatin-mark usage or mark–gene distance were observed 
across the expression reference panels. However, we found that genes with 
associations with multiple chromatin peaks were more likely to be driven by a single 
eQTL (Supplementary Table 14), thus suggesting that multiple chromatin TWAS 
peaks were typically related by a single genetic mechanism. 
We used the measured RNA-seq expression in the chromatin individuals to confirm 
these associations. Across the 806 chromatin TWAS-associated genes, the 
correlation between measured expression and an associated chromatin phenotype 
was highly significant when compared against a distance-matched background null 
(Supplementary Figs. 1e and 14b), and the average TWASassociated chromatin 
peak explained a striking 20% of the variance in expression of its target gene in CEU 
(Supplementary Figs. 25–28 and Supplementary Table 16). For the three chromatin 
phenotypes that were measured in both CEU and YRI, chromatin TWAS peaks 
implicated in one population were predictive of a correlation with measured 
expression in the other (Supplementary Figs. 1f, 29 and 30, and Supplementary 
Table 17), thus supporting our use of chromatin phenotypes from multiple 
populations. 
 
Putative regulatory mechanisms for schizophrenia-associated genes. Focusing 
on the 157 transcriptome-wide-significant genes from the schizophrenia TWAS, we 
identified 42 genes (including seven genes at novel loci) that also had Bonferroni 
significant chromatin TWAS associations (to a total of 78 individual chromatin peaks) 
in analyses using the same expression reference panel (Tables 1 and 2, 
Supplementary Fig. 1h and Supplementary Tables 3, 18 and 19). Only 8 of the 78 
chromatin peaks underlying joint schizophrenia TWAS and chromatin TWAS 
associations were within the promoter (± 2 kb from the TSS) of their associated 
gene, thus suggesting that most regulatory elements affecting schizophrenia are 
distally located, as previously observed in other traits. Schizophrenia TWAS genes 
were nominally enriched in chromatin TWAS associations (odds ratio = 1.53, Fisher's 
exact P = 4 × 10−4), but the effect was largely dampened after matching on the 
cisgenetic properties of genes (P = 0.01; Supplementary Table 20) and may 
potentially be explained by other unknown properties. We observed significant 
evidence of chromatin–schizophrenia association and colocalization for most of the 
identified peaks by using independent statistical methods (Supplementary Fig. 1h). 
We analyzed the subset of schizophrenia TWAS loci with expression– chromatin 
associations by applying COLOC to (i) SNP–expression and SNP–chromatin 
association data to investigate expression– chromatin colocalization and (ii) SNP–
chromatin and SNP–schizophrenia association data to investigate chromatin–
schizophrenia colocalization. Colocalization was observed for 100% of the 
expression– chromatin associations and 97% of the chromatin–schizophrenia 
associations in CEU (Supplementary Fig. 8 and Supplementary Table 19). The 
chromatin associations in YRI pose a model violation for COLOC, owing to 
differences in LD structure between populations, but colocalization still remained 
much higher than background, and 70% (43%) of expression–chromatin (chromatin 
schizophrenia) associations colocalized (Supplementary Fig. 8). Estimating 
pleiotropic associations between chromatin activity and schizophrenia by using 
SMR24 (which tests only the best cQTL) or predicting chromatin activity by using a 
TWAS-like test (testing all SNPs in the Bayesian sparse linear mixed model 
(BSLMM) predictor) replicated > 60% of the associations at Bonferroni significance 
and > 90% at P < 0.05 (Supplementary Note and Supplementary Tables 3, 19 and 
21). However, the chromatin sample size was insufficient to robustly estimate 
genetic predictors of chromatin and carry out a full chromatin-wide association study. 
 
Examples of schizophrenia and chromatin TWAS loci. We highlight three 
examples of TWAS associations with both schizophrenia and chromatin phenotypes. 
We visualized these loci by using a ‘TWAS scatter plot’ of the relationship between 
each marginal GWAS–QTL association (Z score, y axis) and the correlation (x axis) 
between TWAS-predicted expression (GEpred) and the marginal GWAS–QTL 
association. This relationship was expected to be linear and without outliers under 
the TWAS model (Figs. 4 and 5, Supplementary Figs. 32–34 and Supplementary 
Note). First, the total expression of PPP2R3C in NTR blood was associated with 
schizophrenia (TWAS P = 3.4 × 10−6)—despite no genome-wide-significant SNPs at 
the locus—as well as four distal chromatin peaks (minimum P = 1.0 × 10−9; Fig. 4). 
Conditioning each GWAS SNP on the predicted expression of PPP2R3C explained 
all significant marginal associations for the implicated phenotypes, and formal 
colocalization was supported between all features and schizophrenia (average 
posterior = 92%; Supplementary Table 24). PPP2R3C was the nearest gene to the 
most significantly associated SNP at the locus and to the implicated chromatin 
peaks. However, because the locus was not genome-wide significant, this 
association would not have been identified in a conventional analysis of known 
GWAS loci. PPP2R3C has recently been identified by SMR analysis of 
schizophrenia in an independent expression panel, and our findings pinpoint specific 
regulatory elements for experimental follow-up. Second, a splicing event at KLC1 in 
CMC had a schizophrenia TWAS P = 6.7 × 10−12 and overlapping H3K4me1/me3 
chromatin TWAS associations (minimum P = 2.5 × 10−7) (Fig. 5). Conditioning on 
the top splicing QTL explained all significant schizophrenia GWAS signal at the 
locus, whereas conditioning on the most significant eQTL had a negligible effect, 
thus highlighting an effect on schizophrenia that was explained by splicing and was 
independent of total expression. Notably, both chromatin TWAS associations were 
supported by Hi-C interactions with the KLC1 promoter in the developing brain (FDR 
0.01 significant, and the most significant interaction in the locus), thus providing a 
functional validation of coordinated activity (Fig. 5 and Supplementary Fig. 35). We 
performed a TWAS-like test for chromatin–schizophrenia association, which was 
highly significant for both peaks (best P = 2.6 × 10−13; Supplementary Table 3). 
Evidence for colocalization was high for KLC1 splicing and schizophrenia (posterior 
= 58%) as well as for the chromatin phenotypes and both KLC1 splicing and 
schizophrenia (posterior > 80%), even though the chromatin phenotypes were 
identified in YRI and may exhibit LD differences across populations (Supplementary 
Table 24). Differential DNA methylation and expression at KLC1 in schizophrenia 
cases versus controls has recently been identified in two independent analyses of 
brain tissue, thus further supporting a cis-regulatory effect on schizophrenia. Third, 
total expression of MAPK3 in CMC brain data was associated with schizophrenia (P 
= 1.3 × 10−6) as well as two chromatin peaks near the TSS: H3K27ac (P = 7 × 
10−6) and RPB2 (P = 1 × 10−11). In the CEU chromatin phenotype samples, in 
which MAPK3 expression was also measured in LCLs, the H3K27ac and RPB2 
peaks explained 36% (P = 7 × 10−6) and 23% (P = 5 × 10−4) of the variance in 
measured expression, respectively, but only the H3K27ac peak was significant in a 
joint model. Formal colocalization analysis supported a single shared causal variant 
across all eQTL–cQTL– GWAS combinations for the implicated features (posterior 
probabilities 54–97%; Supplementary Table 24). We confirmed that the associated 
peaks were observed in epigenetic data from H3K27ac, H3K4me3 and assay for 
transposase-accessible chromatin using sequencing (ATAC-seq) measured in brain 
tissues and contained two SNPs with significant allele-specific effects on MAPK3 
(Supplementary Note and Supplementary Figs. 36–39). Strikingly, these peaks 
overlapped two recently identified human gained neurodevelopmental enhancers in 
independent fetal cortex tissues  (Supplementary Fig. 36). This class of enhancers 
clusters with genes important for cortical development and neuronal differentiation 
and has been hypothesized to play a key role in human cortical evolution. 
 
Functional interrogation of mapk3 in zebrafish. MAPK3 mapswithin the 16p11.2 
600-kb copy number variant that has beenassociated with both schizophrenia and 
autism. Previous studieshave shown that dosage perturbation of another transcript in 
that region, KCTD13 can induce reciprocal head-size and neuronal proliferative 
defects, characteristics consistent with the anatomical pathology in patients. 
Critically, pairwise dosage analyses haveshown a genetic interaction of KCTD13 
with MAPK3 (as well asa third locus, MVP), whereas independent transcriptional 
studiesin human cells and mouse models have highlighted a functional‘cassette’ 
composed of KCTD13, MVP, and MAPK3, a set of coregulatedgenes associated 
with the head-size phenotype. Togetherwith our TWAS observations, these data 
implicate a transcriptional relationship between these genes in the 16p11.2 region 
and suggest that MAPK3 (and its expression) might be a functional trigger. If so, 
suppression of MAPK3 should rescue the pathology induced by increased 
expression of KCTD13. To test this hypothesis, we performed an experimental assay 
in zebrafish embryos (Methods). In agreement with findings from prior studies, 
overexpression of human KCTD13 (associated with microcephaly in humans) 
induced both a decrease in head size and a concomitant decrease in the number of 
cycling cells in the brain (Fig. 6). However, suppression of endogenous mapk3 in 
KCTD13-overexpressing embryos rescued both phenotypes reproducibly (Fig. 6). 
 
Discussion 
The landmark PGC schizophrenia GWAS paper has concluded that “if most risk 
variants are regulatory, available eQTL catalogues do not yet provide power, cellular 
specificity, or developmental diversity to provide clear mechanistic hypotheses for 
follow-up experiments” In this work, we integrated data from GWAS, expression, 
splicing, and chromatin activity to identify mechanistic hypotheses. We found 157 
unique genes with transcriptome-wide-significant associations with schizophrenia, 
which were significantly supported by chromatin contact measured during brain 
development. Genes below the transcriptome-wide-significance threshold continued 
to be strongly associated with schizophrenia and exhibited enrichment for expression 
and splicing in the brain (though this result may also reflect expression-data quality). 
Associations for splicing events that were independent of total expression highlighted 
an important source of disease-relevant variation27 with potential therapeutic 
implications. Notably, 42 of the 157 schizophrenia-associated genes were 
significantly associated with nearby chromatin phenotypes, thus implicating specific 
regulatory features for functional follow-up. We interrogated one TWAS association, 
MAPK3, in zebrafish embryos and observed a significant effect on 
neurodevelopmental phenotypes with consistent direction; thus, we prioritized this as 
a candidate for further follow-up. We conclude with several limitations and future 
directions of this study. First, although TWAS is not confounded by reverse causality 
(disease → expression independent of SNP), instances of pleiotropy (in which a 
SNP or linked SNPs influence schizophrenia and expression independently) are 
statistically indistinguishable from truly causal susceptibility genes. As more 
molecular studies are performed, and the chance of incidental QTL–GWAS overlap 
increases, experimental causal inference is necessary to validate these findings. 
Second, the chromatin phenotypes analyzed here were measured in LCLs (because 
population-level chromatin data from other tissues are currently unavailable), thus 
preventing us from identifying brain-specific expression–chromatin associations. 
Third, the use of summary-based data necessitates linear predictors of expression, 
which may lead to misinterpretation of relationships between expression and 
disease/chromatin, if, for example, the weaker/secondary eQTLs/cQTLs have 
stronger effects on the trait because of context specificity. Finally, although we did 
not observe significant pathway/ontology enrichment for the identified susceptibility 
genes, we posit that these genes and chromatin features may serve as anchors for 
network-based analyses of genomewide coexpression and co-regulation; we view 
this direction as an intriguing prospect for future investigation. 
 
Because tissue acquisition may pose the greatest hurdle for producing larger 
datasets, methods that do not depend on measurements from the same samples will 
remain critical. Beyond specific mechanistic findings for schizophrenia, this work 






TWAS associations (minimum P = 2.5 × 10−7) (Fig. 5). Conditioning on the top 
splicing QTL explained all significant schizophrenia GWAS signal at the locus, 
whereas conditioning on the most significant eQTL had a negligible effect, thus 
highlighting an effect on schizophrenia that was explained by splicing and was 
independent of total expression. Notably, both chromatin TWAS associations were 
supported by Hi-C interactions with the KLC1 promoter in the developing brain33 
(FDR 0.01 significant, and the most significant interaction in the locus), thus 
providing a functional validation of coordinated activity (Fig. 5 and Supplementary 
Fig. 35). We performed a TWAS-like test for chromatin–schizophrenia association, 
which was highly significant for both peaks (best P = 2.6 × 10−13; Supplementary 
Table 3). Evidence for colocalization was high for KLC1 splicing and schizophrenia 
(posterior = 58%) as well as for the chromatin phenotypes and both KLC1 splicing 
and schizophrenia (posterior > 80%), even though the chromatin phenotypes were 
identified in YRI and may exhibit LD differences across populations (Supplementary 
Table 24). Differential DNA methylation40 and expression at KLC1 in schizophrenia 
cases versus controls has recently been identified in two independent analyses of 
brain tissue, thus further supporting a cis-regulatory effect on schizophrenia.  
 
Third, total expression of MAPK3 in CMC brain data was associated with 
schizophrenia (P = 1.3 × 10−6) as well as two chromatin peaks near the TSS: 
H3K27ac (P = 7 × 10−6) and RPB2 (P = 1 × 10−11). In the CEU chromatin 
phenotype samples, in which MAPK3 expression was also measured in LCLs, the 
H3K27ac and RPB2 peaks explained 36% (P = 7 × 10−6) and 23% (P = 5 × 10−4) of 
the variance in measured expression, respectively, but only the H3K27ac peak was 
significant in a joint model. Formal colocalization analysis supported a single shared 
causal variant across all eQTL–cQTL– GWAS combinations for the implicated 
features (posterior probabilities 54–97%; Supplementary Table 24). We confirmed 
that the associated peaks were observed in epigenetic data from H3K27ac, 
H3K4me3 and assay for transposase-accessible chromatin using sequencing 
(ATAC-seq) measured in brain tissues41 and contained two SNPs with significant 
allele-specific effects42 on MAPK3 (Supplementary Note and Supplementary Figs. 
36–39). Strikingly, these peaks overlapped two recently identified human gained 
neurodevelopmental enhancers in independent fetal cortex tissues43 
(Supplementary Fig. 36). This class of enhancers clusters with genes important for 
cortical development and neuronal differentiation and has been hypothesized to play 
a key role in human cortical evolution. 
 
Functional interrogation of mapk3 in zebrafish. MAPK3 maps within the 16p11.2 
600-kb copy number variant that has been associated with both schizophrenia and 
autism44–48. Previous studies have shown that dosage perturbation of another 
transcript in that region, KCTD13 can induce reciprocal head-size and neuronal 
pathology in patients44. Critically, pairwise dosage analyses have shown a genetic 
interaction of KCTD13 with MAPK3 (as well as a third locus, MVP)44, whereas 
independent transcriptional studies in human cells and mouse models have 
highlighted a functional ‘cassette’ composed of KCTD13, MVP, and MAPK3, a set of 
coregulated genes associated with the head-size phenotype47. Together with our 
TWAS observations, these data implicate a transcriptional relationship between 
these genes in the 16p11.2 region and suggest that MAPK3 (and its expression) 
might be a functional trigger. If so, suppression of MAPK3 should rescue the 
pathology induced by increased expression of KCTD13. To test this hypothesis, we 
performed an experimental assay in zebrafish embryos (Methods). In agreement 
with findings from prior studies, overexpression of human KCTD13 (associated with 
microcephaly in humans) induced both a decrease in head size and a concomitant 
decrease in the number of cycling cells in the brain (Fig. 6). However, suppression of 
endogenous mapk3 in KCTD13-overexpressing embryos rescued both phenotypes 
reproducibly (Fig. 6). 
 
Discussion 
The landmark PGC schizophrenia GWAS paper has concluded that “if most risk 
variants are regulatory, available eQTL catalogues do not yet provide power, cellular 
specificity, or developmental diversity to provide clear mechanistic hypotheses for 
follow-up experiments”. In this work, we integrated data from GWAS, expression, 
splicing, and chromatin activity to identify mechanistic hypotheses. We found 157 
unique genes with transcriptome-wide-significant associations with schizophrenia, 
which were significantly supported by chromatin contact measured during brain 
development. Genes below the transcriptome-wide-significance threshold continued 
to be strongly associated with schizophrenia and exhibited enrichment for expression 
and splicing in the brain (though this result may also reflect expression-data quality). 
Associations for splicing events that were independent of total expression highlighted 
an important source of disease-relevant variation with potential therapeutic 
implications. Notably, 42 of the 157 schizophrenia-associated genes were 
significantly associated with nearby chromatin phenotypes, thus implicating specific 
regulatory features for functional follow-up. We interrogated one TWAS association, 
MAPK3, in zebrafish embryos and observed a significant effect on 
neurodevelopmental phenotypes with consistent direction; thus, we prioritized this as 
a candidate for further follow-up. 
We conclude with several limitations and future directions of this study. First, 
although TWAS is not confounded by reverse causality (disease → expression 
independent of SNP), instances of pleiotropy (in which a SNP or linked SNPs 
influence schizophrenia and expression independently) are statistically 
indistinguishable from truly causal susceptibility genes. As more molecular studies 
are performed, and the chance of incidental QTL–GWAS overlap increases, 
experimental causal inference is necessary to validate these findings. Second, the 
chromatin phenotypes analyzed here were measured in LCLs (because population-
level chromatin data from other tissues are currently unavailable), thus preventing us 
from identifying brain-specific expression–chromatin associations.Third, the use of 
summary-based data necessitates linear predictors of expression, which may lead to 
misinterpretation of relationships between expression and disease/chromatin, if, for 
example, the weaker/secondary eQTLs/cQTLs have stronger effects on the trait 
because of context specificity. Finally, although we did not observe significant 
pathway/ontology enrichment for the identified susceptibility genes, we posit that 
these genes and chromatin features may serve as anchors for network-based 
analyses of genomewide coexpression and co-regulation; we view this direction as 
an intriguing prospect for future investigation. 
Because tissue acquisition may pose the greatest hurdle for producing larger 
datasets, methods that do not depend on measurements from the same samples will 
remain critical. Beyond specific mechanistic findings for schizophrenia, this work 
outlines a systematic approach to identify functional mediators of complex disease. 
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